2018 年第三季度报告 公司代码：603567 公司简称：珍宝岛 黑龙江珍宝岛药业股份有限公司 2018 年第三季度报告 1 / 21 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 9 | 2018 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 7,443,847,600.27 6,886,060,710.34 8.10 归属于上市公司 股东的净资产 4,883,388,546.77 4,669,436,334.53 4.58 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减(%) 经营活动产生的 现金流量净额 279,128,500.88 268,875,172.16 3.81 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减 （%） 营业收入 1,977,424 ...

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 1,262,746,785.14, representing an increase of 8.48% compared to CNY 1,164,036,145.73 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 248,168,500.55, up 24.38% from CNY 199,522,754.26 year-on-year[19]. - The net profit after deducting non-recurring gains and losses was CNY 172,854,753.58, an increase of 14.66% compared to CNY 150,747,694.18 in the previous year[19]. - Basic earnings per share for the first half of 2018 were CNY 0.2923, a 24.38% increase from CNY 0.2350 in the same period last year[20]. - The diluted earnings per share also stood at CNY 0.2923, reflecting the same growth rate of 24.38% year-on-year[20]. - The weighted average return on net assets increased by 0.65 percentage points to 5.18% from 4.53% in the previous year[20]. - The company reported a total non-operating income of 75,313,746.97, after accounting for income tax effects of -14,713,412.79[24]. - The company reported a significant increase in revenue, achieving a total of 859.78 million RMB during the reporting period[87]. - The total operating revenue for the current period reached ¥1,263,905,245.18, an increase of 8.23% from ¥1,167,523,468.06 in the previous period[122]. - Operating profit for the current period was ¥295,634,432.23, up 50.29% from ¥196,661,336.88 in the previous period[123]. - Net profit for the current period was ¥248,759,229.94, representing a 23.26% increase compared to ¥201,787,662.22 in the previous period[123]. Cash Flow and Assets - The net cash flow from operating activities decreased by 68.24%, amounting to CNY 77,257,860.23, down from CNY 243,259,689.21 in the same period last year[19]. - Cash and cash equivalents at the end of the period amounted to ¥1,714,590,051.08, a decrease of 4.62% compared to the previous period[65]. - Inventory increased significantly to ¥1,666,990,073.46, representing a 44.65% increase, primarily due to increased development costs[65]. - Short-term borrowings rose to ¥1,600,000,000.00, reflecting a 14.29% increase from the previous period[65]. - Accounts receivable decreased slightly to ¥1,057,360,881.32, a decline of 0.17%[65]. - The total assets at the end of the reporting period were CNY 7,130,930,370.75, reflecting a 3.56% increase from CNY 6,886,060,710.34 at the end of the previous year[19]. - The company's cash and cash equivalents decreased from ¥1,797,673,998.43 to ¥1,714,590,051.08, a decline of approximately 4.6%[114]. - Total current assets rose from ¥4,522,552,454.06 to ¥4,915,062,920.39, an increase of about 8.7%[114]. - The total liabilities rose to CNY 2,360,905,157.53, compared to CNY 2,206,906,759.03, indicating an increase of about 6.97%[116]. - Current liabilities totaled CNY 2,214,947,199.12, an increase from CNY 2,062,414,427.88, reflecting a growth of approximately 7.37%[116]. Research and Development - The company completed 11 invention patent applications and received 4 invention patent authorizations in the first half of 2018[27]. - The company has 15 chemical raw materials and 27 chemical formulations under research, focusing on cardiovascular, oncology, respiratory, digestive, diabetes, and pediatric treatment areas[47]. - Research and development expenditure rose by 38.87% to approximately ¥46 million, indicating a commitment to enhancing R&D capabilities[63]. - The company completed the registration application for the innovative drug AKT kinase inhibitor HZB0071, marking a significant step in its R&D capabilities[57]. - The pharmaceutical industry is experiencing a surge in innovation, with the company needing to integrate internationalization and research innovation to enhance its R&D capabilities[39]. Marketing and Sales Strategy - The company has established a multi-channel marketing strategy combining direct sales, refined招商, and channel distribution to enhance competitiveness[49]. - The company has established strategic partnerships with leading suppliers to reduce procurement costs and enhance quality[30]. - The company operates under a "sales-driven production" model, ensuring production plans are aligned with sales forecasts and inventory levels[33]. - The company has implemented a dynamic analysis platform for market prices to enhance supplier performance management[28]. - The company has established offices in key traditional Chinese medicine (TCM) production areas and created a strategic reserve system to mitigate procurement cost fluctuations due to market price volatility[73]. Corporate Governance and Compliance - The company has not proposed any profit distribution or capital reserve increase for the first half of 2018[80]. - The company has committed to not transferring or managing its shares for 36 months post-IPO, ensuring stability in shareholding[86]. - The company has maintained compliance with all regulatory commitments and has accepted supervision from regulatory bodies[86]. - The company has not reported any major litigation or arbitration matters during the reporting period[86]. - The company has not disclosed any significant related party transactions during the reporting period[89]. Social Responsibility and Community Engagement - The company invested over 174,047 RMB (approximately 17.4 million RMB) in poverty alleviation efforts during the first half of 2018[91]. - The company provided 120,000 RMB (approximately 12 million RMB) in scholarships to impoverished students as part of its educational poverty alleviation initiatives[93]. - The company conducted a large-scale free clinic and donated medicines valued at over 20,000 RMB (approximately 2 million RMB) to assist over 370 patients in a national-level poverty-stricken county[94]. - The company organized various social welfare activities, including donations to local elderly care facilities and police departments, totaling over 10,000 RMB (approximately 1 million RMB) in value[98]. - The company plans to continue its poverty alleviation efforts by expanding its support to more regions and establishing additional public welfare funds[99]. Environmental Responsibility - The company has implemented environmental protection measures, including the introduction of new wastewater treatment facilities to enhance its environmental compliance[100]. - The company is committed to ongoing clean production audits to reduce pollutant emissions and improve environmental quality[101]. Accounting and Financial Reporting - The company prepares its financial statements based on the going concern assumption, with no significant issues affecting its ability to continue operations for at least 12 months from the reporting date[156]. - The company adopts the accrual basis of accounting, recognizing revenue and expenses when they are incurred, rather than when cash is received or paid[155]. - The company assesses the recoverability of receivables and inventories, with provisions for bad debts and inventory write-downs based on management's estimates and judgments[158]. - The company follows specific accounting policies for revenue recognition and research and development expenditures, tailored to its operational characteristics[157]. - The company’s accounting policies are in compliance with the relevant accounting standards and accurately reflect its financial position and performance[163].

2018 年第一季度报告 公司代码：603567 公司简称：珍宝岛 黑龙江珍宝岛药业股份有限公司 2018 年第一季度报告 1 / 17 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 7 | 2018 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 非经常性损益项目和金额 √适用 □不适用 | | 单位：元 币种：人民币 | | | --- | --- | --- | | 项目 | 本期金额 | 说明 | | 非流动资产处置损益 | -113,595.53 | | | 越权审批，或无正式批准文件，或偶发性的税收返还、减免 | | | | 计入当期损益的政府补助，但与公司正常经营业务密切相关，符合 | 46,214,035.77 | | 3 / 17 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度 末增减(%) 总资产 7,009,944,150.2 4 6,886,060,710.34 1.80 归属于上市公司股东的净 资产 4,826,437,332.0 9 4, ...

Financial Performance - The company's operating revenue for 2017 was RMB 3,136,522,106.74, representing a 31.17% increase compared to RMB 2,391,235,153.18 in 2016[21] - The net profit attributable to shareholders for 2017 was RMB 520,872,588.42, a slight increase of 2.22% from RMB 509,560,904.81 in the previous year[21] - The net profit after deducting non-recurring gains and losses was RMB 469,013,458.28, which is a 31.18% increase from RMB 357,545,403.05 in 2016[21] - The net cash flow from operating activities surged to RMB 853,192,181.38, a significant increase from RMB 15,825,550.53 in 2016, marking a growth of 5,291.23%[21] - The total assets at the end of 2017 were RMB 6,886,060,710.34, reflecting a 7.28% increase from RMB 6,418,989,445.45 in 2016[22] - The net assets attributable to shareholders increased to RMB 4,669,436,334.53, an 8.56% rise from RMB 4,301,238,377.80 in 2016[22] - The basic earnings per share for 2017 was RMB 0.6134, up 2.22% from RMB 0.6001 in 2016[23] - The weighted average return on net assets was 11.61%, a decrease of 0.66 percentage points from 12.27% in 2016[23] Revenue Growth Drivers - The growth in operating revenue was primarily driven by the increase in pharmaceutical commerce and traditional Chinese medicine sales[23] - In Q1 2017, the operating revenue was approximately CNY 547.22 million, while in Q4 2017, it rose to approximately CNY 1.21 billion, indicating a significant growth[26] - The net profit attributable to shareholders was CNY 117.40 million in Q1 2017 and increased to CNY 166.17 million in Q4 2017[26] Research and Development - The company reported a total of 32 patent applications in 2017, including 26 invention patents and 6 design patents, with 16 patents granted[32] - The company has established a post-doctoral research workstation and key laboratories to enhance its research and development capabilities[48] - The company has 18 chemical raw materials and 30 chemical preparations under research, including 3 new class I drugs[97] - The R&D investment for the reporting period amounted to 93.74 million RMB, accounting for 2.99% of operating revenue[101] Product and Market Strategy - The company’s main products include injection blood stasis solution (freeze-dried), blood circulation injection solution, and injection bone peptide[32] - The company has established strategic partnerships with leading suppliers to reduce procurement costs and enhance quality, ultimately improving overall efficiency and competitiveness[35] - The marketing strategy includes a multi-model approach with a focus on self-operated sales, covering 12,000 grade hospitals, 39,000 grassroots hospitals, and 17,000 OTC pharmacies nationwide[38] - The company added two new medical insurance products, which have boosted sales through its self-operated sales team targeting grade hospitals[38] Quality Control and Compliance - The company adheres to strict GMP standards in production, ensuring consistent and reliable product quality[35] - The company established a quality control system that exceeds national drug standards, ensuring the integrity and reliability of drug testing data through a networked instrument detection system[46] - The company has implemented measures to enhance product quality control, including full inspection of raw materials and packaging according to the latest national standards[149] Social Responsibility and Community Engagement - The company actively participates in social welfare and poverty alleviation initiatives, supporting local education, culture, and health sectors[170] - In 2017, the company donated 47.55 million RMB for poverty alleviation efforts, including 5 million RMB for educational support[174] - The company constructed two bridges in Shuiqi Village to improve transportation for local farmers, addressing seasonal travel difficulties[171] - The company received multiple awards for its contributions to social responsibility, including the "Outstanding Youth Volunteer Service Contribution Unit" title[175] Corporate Governance and Management - The company has a strong management team with extensive experience in the pharmaceutical industry[200] - The current board includes professionals with backgrounds in finance, production, and pharmaceutical research[200] - The management team includes individuals with advanced degrees and specialized training in their respective fields[200] - The company has maintained a stable leadership structure with key personnel serving in various capacities over the years[200] Financial Health and Investments - The company has a total of ¥51,008,329.19 in restricted assets, primarily due to bank acceptance bill guarantees and pledges for issuing bank acceptance bills[84][85] - The company has invested 50 million RMB in technology upgrades to improve production efficiency, aiming for a 15% reduction in operational costs[199] - The company plans to leverage favorable macroeconomic conditions and policy reforms to achieve a projected 16.5% growth in pharmaceutical sales revenue over the next five years[128] Market Trends and Industry Outlook - The Chinese pharmaceutical industry is expected to grow to 3.3292 trillion yuan in 2017, representing a year-on-year increase of 13%[39] - The health service industry in China is projected to grow significantly, with a compound annual growth rate of approximately 27.26% over the next five years[40] - The overall pharmaceutical market growth rate is projected to increase from 7.6% in 2017 to 8% in 2018, with the first terminal growing by 7% to 7.3%, the second terminal from 8% to 8.6%, and the third terminal slightly decreasing from 11.6% to 11.5%[131]

[Important Notice](index=3&type=section&id=一、%20重要提示) [Statement on Report Authenticity and Audit Status](index=3&type=section&id=1.1-1.4) The company's board of directors, supervisory board, and senior management ensure the truthfulness, accuracy, and completeness of this quarterly report, assuming corresponding legal responsibilities; all directors attended the board meeting to review this report, which remains unaudited - The company's management (board of directors, supervisory board, and senior executives) guarantees the truthfulness, accuracy, and completeness of the quarterly report, free from false records, misleading statements, or major omissions[5](index=5&type=chunk) - This company's Q3 2017 report is unaudited[5](index=5&type=chunk) [Company Overview](index=3&type=section&id=二、%20公司基本情况) [Key Financial Data](index=3&type=section&id=2.1%20主要财务数据) In the first three quarters of 2017, the company's operating revenue increased by **32.05%**, while net profit attributable to shareholders decreased by **6.50%**, though net profit after non-recurring items grew by **16.87%**, and operating cash flow significantly improved to a net inflow of **269 million yuan** Key Financial Indicators for Q1-Q3 2017 (Jan-Sep) | Indicator | Jan-Sep 2017 (yuan) | Jan-Sep 2016 (yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 1,923,676,748.32 | 1,456,759,482.41 | 32.05% | | Net Profit Attributable to Listed Company Shareholders | 354,706,458.84 | 379,346,081.20 | -6.50% | | Net Profit Attributable to Parent Company Shareholders (Excluding Non-Recurring Items) | 302,007,877.74 | 258,415,283.83 | 16.87% | | Net Cash Flow from Operating Activities | 268,875,172.16 | -228,996,852.48 | 217.41% | Non-Recurring Gains and Losses for Q1-Q3 2017 (Jan-Sep) | Item | Amount (yuan) | Description | | :--- | :--- | :--- | | Government grants included in current profit/loss | 61,908,600.68 | - | | Gains/losses from entrusted investment or asset management | 4,419,136.15 | - | | **Total** | **52,698,581.10** | - | [Shareholder Information](index=4&type=section&id=2.2%20股东情况) As of the end of the reporting period, the company had **31,050 shareholders**, with a highly concentrated equity structure where the top two shareholders collectively held **84.79%** of shares - As of the end of the reporting period, the company had a total of **31,050 shareholders**[8](index=8&type=chunk) Top Two Shareholders' Holdings | Shareholder Name | Shares Held | Percentage (%) | | :--- | :--- | :--- | | Hulin Chuangda Investment Co., Ltd. | 576,000,000 | 67.83 | | Hulin Longpeng Investment Center (Limited Partnership) | 144,000,000 | 16.96 | [Significant Matters](index=6&type=section&id=三、%20重要事项) [Analysis of Significant Changes in Financial Statement Items](index=6&type=section&id=3.1%20公司主要会计报表项目、财务指标重大变动的情况及原因) During the reporting period, the company experienced significant changes in financial metrics, including substantial increases in accounts receivable and construction in progress due to expanded pharmaceutical distribution and traditional Chinese medicine trading projects, alongside improved operating cash flow from increased sales collections and reduced financing cash flow due to loan repayments - Accounts receivable increased by **71.89%** from the beginning of the year, primarily due to the company's increased market share in pharmaceutical commercial distribution during the reporting period[10](index=10&type=chunk) - Construction in progress increased by **92.41%** from the beginning of the year, mainly due to investments in traditional Chinese medicine commodity trading projects during the reporting period[10](index=10&type=chunk) - Net cash flow from operating activities increased by **217.41%** year-over-year, primarily due to increased sales collections, while net cash flow from financing activities decreased by **255.86%** year-over-year, mainly due to loan repayments[12](index=12&type=chunk) [Other Significant Matters](index=8&type=section&id=3.2-3.4%20其他重要事项) During the reporting period, the company had no significant matter progress, overdue unfulfilled commitments, or warnings regarding potential major changes in future performance - The company had no significant matter progress or overdue unfulfilled commitments during this reporting period, nor did it forecast any major changes in cumulative net profit from the beginning of the year to the end of the next reporting period[13](index=13&type=chunk) [Appendix](index=9&type=section&id=四、%20附录) [Financial Statements](index=9&type=section&id=4.1%20财务报表) The appendix provides the company's unaudited consolidated and parent company financial statements, including the balance sheet, income statement, and cash flow statement, detailing the financial position as of September 30, 2017, and operating results for the first three quarters [Consolidated Balance Sheet](index=9&type=section&id=合并资产负债表) As of September 30, 2017, the company's total assets were **6.37 billion yuan**, a slight decrease of **0.83%** from the beginning of the year, while total liabilities decreased by **12.31%** to **1.85 billion yuan** primarily due to reduced short-term borrowings, and equity attributable to parent company owners increased by **4.70%** to **4.50 billion yuan** Consolidated Balance Sheet Key Items (2017-09-30) | Item | Period-End Balance (yuan) | Year-Beginning Balance (yuan) | | :--- | :--- | :--- | | Total Assets | 6,365,846,811.50 | 6,418,989,445.45 | | Total Liabilities | 1,852,260,537.63 | 2,112,360,802.89 | | Total Equity Attributable to Parent Company Owners | 4,503,326,752.39 | 4,301,238,377.80 | [Consolidated Income Statement](index=13&type=section&id=合并利润表) In the first three quarters of 2017, the company achieved total operating revenue of **1.93 billion yuan**, a **32.34%** increase year-over-year, with operating costs growing faster at **50.59%**, resulting in a net profit attributable to parent company owners of **355 million yuan**, a **6.50%** decrease year-over-year Consolidated Income Statement Key Items (Jan-Sep 2017) | Item | Jan-Sep 2017 (yuan) | Jan-Sep 2016 (yuan) | | :--- | :--- | :--- | | Total Operating Revenue | 1,927,855,726.89 | 1,456,759,482.41 | | Operating Costs | 782,699,242.11 | 519,754,270.51 | | Net Profit Attributable to Parent Company Owners | 354,706,458.84 | 379,346,081.20 | | Basic Earnings Per Share (yuan/share) | 0.4177 | 0.4467 | [Consolidated Cash Flow Statement](index=17&type=section&id=合并现金流量表) In the first three quarters of 2017, net cash flow from operating activities significantly improved to **269 million yuan** from a **229 million yuan** outflow in the prior year, while net cash flow from investing activities was **128 million yuan** primarily due to investment recovery, and net cash outflow from financing activities was **406 million yuan** mainly for debt repayment, with cash and cash equivalents totaling **1.16 billion yuan** at period-end Consolidated Cash Flow Statement Key Items (Jan-Sep 2017) | Item | Jan-Sep 2017 (yuan) | Jan-Sep 2016 (yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 268,875,172.16 | -228,996,852.48 | | Net Cash Flow from Investing Activities | 127,758,959.11 | -22,361,672.99 | | Net Cash Flow from Financing Activities | -405,828,462.31 | 260,376,411.02 | | Cash and Cash Equivalents at Period-End | 1,162,656,583.11 | 1,327,369,075.39 | [Audit Report](index=20&type=section&id=4.2%20审计报告) The report explicitly states that this quarterly financial report is unaudited - This quarterly report is unaudited[36](index=36&type=chunk)

Financial Performance - The company's operating revenue for the first half of 2017 was CNY 1,164,036,145.73, representing a 25.63% increase compared to CNY 926,539,181.14 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was CNY 199,522,754.26, a decrease of 4.17% from CNY 208,204,644.94 in the previous year[16]. - The net cash flow from operating activities increased by 177.04%, reaching CNY 243,259,689.21, compared to a negative cash flow of CNY -315,774,581.17 in the same period last year[16]. - The total assets decreased by 7.27% to CNY 5,952,483,674.61 from CNY 6,418,989,445.45 at the end of the previous year[16]. - The company reported a basic earnings per share of CNY 0.2350, down 4.16% from CNY 0.2452 in the same period last year[17]. - The company achieved a revenue of CNY 1,164,036,145.73, representing a year-on-year growth of 25.63%[48]. - The net profit attributable to shareholders was CNY 19,952,280, a decrease of 4.17% compared to the previous year[45]. - The company reported a significant increase in R&D expenditure, amounting to CNY 33,108,035.45, which is a 61.87% increase year-on-year[48]. - The company reported a total of 1,201,702,032.57 RMB in cash inflows from investment activities, while cash outflows amounted to 1,047,827,377.93 RMB, resulting in a net inflow of 153,874,654.64 RMB[115]. Research and Development - The company has submitted 16 patent applications in the first half of 2017, including 11 invention patents[23]. - The company has established a research and development model that combines independent research, external cooperation, and technology introduction, aiming to expand its pharmaceutical portfolio[40]. - The company has achieved significant clinical advantages with its injectable blood stasis drug and Shuxue Ning injection, reaching international advanced levels in technology[36]. - The company has implemented over 10 advanced technologies in production, enhancing product quality and technological content[37]. - Investment in research and development has increased by 30%, focusing on innovative drug formulations and advanced medical technologies[138]. Product and Market Development - The company has 27 products listed in the National Medical Insurance Directory and 12 in the National Essential Medicines List[22]. - The company’s main products include blood-sealing injection and blood circulation injection, among others[22]. - The company has established a retail channel network covering 30 provinces and municipalities, directly cooperating with 1,192 commercial entities and covering over 6,000 secondary hospitals and more than 35,000 grassroots medical institutions[34]. - The company is actively pursuing new product development and has initiated a project for the training of high-potential university students to strengthen its talent pool[43]. - The company has introduced two new products in the market, which are anticipated to contribute an additional 100 million RMB in revenue over the next year[136]. Financial Position and Assets - The total profit for the pharmaceutical industry reached 125.5 billion CNY, with a year-on-year increase of 15.7%[30]. - The company's total assets decreased to CNY 4,970,283,570.45 from CNY 5,500,297,112.33, a decline of 9.6% year-over-year[102]. - Total liabilities decreased to CNY 776,797,089.20 from CNY 1,340,380,134.49, a reduction of 42.0% compared to the previous year[102]. - The company's total equity increased to CNY 4,193,486,481.25 from CNY 4,159,916,977.84, reflecting a growth of 0.8% year-over-year[102]. - The company has a total of 71,914,946.10 CNY in restricted assets, primarily due to bank acceptance bill guarantees and accounts receivable factoring[52]. Compliance and Risk Management - There are no significant risks that could materially affect the company's production and operations during the reporting period[3]. - The company is committed to maintaining compliance with evolving drug registration and regulatory policies to ensure successful product launches[60]. - The company faces significant risks in drug research and development due to high investment, long cycles, and potential product obsolescence[58]. - The company is enhancing its policy interpretation and analysis capabilities to adapt its business strategies in response to regulatory changes and market trends[57]. - The company has adopted a risk warning and prevention-based multi-level internal control quality standard system to ensure product quality throughout the production process[39]. Environmental and Social Responsibility - The company emphasizes its commitment to environmental protection, implementing measures such as enhanced wastewater treatment capabilities and pollution prevention facilities[81]. - The company initiated a poverty alleviation project in Shuqi Village, with a total contract amount of CNY 297,300 for the construction of two bridges, expected to be completed by the end of August 2017[76]. - The company plans to continue supporting infrastructure development in Shuqi Village to enhance both material and spiritual civilization construction[79]. - The company regularly discloses environmental protection information to the public, promoting transparency and accountability[81]. - All major subsidiaries have implemented clean production audits, effectively reducing pollutant emissions through various measures[81]. Corporate Governance - The board of directors and senior management saw changes, including the election of new members and the appointment of new vice presidents[90]. - The company has not experienced any changes in accounting policies or significant accounting errors during the reporting period[82]. - The company has not proposed any profit distribution or capital reserve increase for the half-year period[66]. - The total number of common stock shareholders at the end of the reporting period was 31,178[84]. - The largest shareholder, Hulin Chuangda Investment Co., Ltd., holds 576,000,000 shares, representing 67.83% of the total shares, with 154,900,000 shares pledged[86].

Financial Performance - The company's operating revenue for 2016 was RMB 2,391,235,153.18, representing a 15.35% increase compared to RMB 2,073,059,862.24 in 2015[20] - The net profit attributable to shareholders of the listed company decreased by 12.94% to RMB 509,560,904.81 from RMB 585,305,007.62 in the previous year[20] - The net profit after deducting non-recurring gains and losses was RMB 357,545,403.05, down 36.84% from RMB 566,088,030.07 in 2015[20] - Basic earnings per share decreased by 58.68% to CNY 0.6001 from CNY 1.4522 in the previous year[22] - The company achieved a revenue of 2.391 billion yuan in 2016, representing a year-on-year growth of 15.35%[52] - The net profit attributable to shareholders was 510 million yuan, a decrease of 12.94% compared to the previous year[62] - Operating costs rose to 848.51 million RMB, an increase of 86.84% compared to the previous year[64] - The gross profit margin for the industrial sector was 77.69%, a decrease of 3.56 percentage points year-on-year[66] Cash Flow and Assets - The net cash flow from operating activities improved significantly to RMB 15,825,550.53, a 104.89% increase from a negative RMB 323,895,033.93 in 2015[20] - The total assets of the company at the end of 2016 were RMB 6,418,989,445.45, reflecting a 7.89% increase from RMB 5,949,674,930.57 in 2015[20] - The company reported a net cash flow from operating activities of 15.83 million RMB, a turnaround from a negative cash flow of 323.90 million RMB in the previous year[64] - The company reported a decrease in cash and cash equivalents by 30.75% due to investments in financial products and dividend distributions totaling CNY 396 million and CNY 212 million respectively[81] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of RMB 1.81 per 10 shares, totaling RMB 153,697,960.00[4] - In 2016, the company distributed cash dividends amounting to CNY 153,697,960, representing 30.16% of the net profit attributable to ordinary shareholders[145] - The cash dividend for 2015 was CNY 212,290,000, which accounted for 36.27% of the net profit attributable to ordinary shareholders[145] - The cash dividend for 2014 was CNY 200,000,000, representing 41.90% of the net profit attributable to ordinary shareholders[145] Research and Development - The company reported a total of 29 patent applications in 2016, with 10 patents granted, including 7 invention patents[32] - The company has 19 pharmaceutical products under research, including 3 new drugs, with a focus on areas such as antibiotics, anti-tumor, cardiovascular, diabetes, and digestive system[96] - The total R&D investment for the reporting period was 7,092.68 million RMB, accounting for 2.97% of operating revenue[99] - The company is enhancing its R&D efforts to develop a comprehensive range of products, including modern traditional Chinese medicine, high-quality chemical drugs, and innovative biopharmaceuticals[133] Market and Product Development - The company’s main business includes the production and sale of traditional Chinese medicine, with a focus on cardiovascular drugs[31] - The company is expanding its business into commercial distribution and traditional Chinese medicine trading[32] - The company has established a retail channel network covering 30 provinces and municipalities, directly cooperating with 902 commercial partners and covering over 6,000 secondary medical institutions[39] - The company’s products, including Xiaer Resuqing Syrup and Compound Qilan Oral Liquid, were added to the new national medical insurance directory, creating new profit growth points[59] Quality Control and Compliance - The company emphasizes strict quality control, with internal standards exceeding national drug standards, ensuring high-quality pharmaceutical products[44] - The company established a quality management system that complies with GMP standards, ensuring product quality from raw materials to finished products[52] - The company has implemented a dual procurement model for traditional Chinese medicine, investing in local planting companies to control the quality and supply of raw materials[35] Risks and Challenges - There were no significant risks that materially affected the company's operations during the reporting period[6] - The company faces risks related to product quality and technology updates, which could impact market share and profitability[138] - The company is addressing procurement risks by strategically analyzing market prices and establishing cultivation companies for key raw materials[141] Social Responsibility and Community Engagement - The company actively participated in social welfare and poverty alleviation activities, purchasing agricultural products worth CNY 633,600 in June 2016 to support local farmers[169] - The company plans to continue purchasing surplus agricultural products to increase farmers' income and address overproduction issues[172] - The company intends to fund the construction of two bridges to improve transportation and safety for villagers during rainy seasons[173] Corporate Governance and Structure - The company has not engaged in any mergers or acquisitions during the reporting period[193] - The company has not faced any risks of suspension or termination of listing[154] - The actual controller, Fang Tonghua, is also the chairman and general manager of the company[194]

公司代码：603567 公司简称：珍宝岛 黑龙江珍宝岛药业股份有限公司 2017 年第一季度报告 1 / 18 | 一、重要提示 | 3 | | --- | --- | | 二、公司基本情况 | 3 | | 三、重要事项 | 6 | | 四、附录 | 8 | 2017 年第一季度报告 2017 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | | | 单位：元 币种：人民币 | | | --- | --- | --- | --- | --- | | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | | | | 减(%) | | | 总资产 | 6,299,423,916.91 | 6,418,989,445.45 | | -1.86 | | 归属于上市公司 | 4,419,036,868.82 | 4,301,238,377.80 | | 2.74 | | 股东的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的 现金流量净额 | 95,253,465.76 | -284,338 ...

Financial Performance - Net profit attributable to shareholders rose by 28.82% to CNY 379,346,081.20 for the first nine months of the year[7]. - Operating revenue for the first nine months increased by 14.92% to CNY 1,456,759,482.41 compared to the same period last year[7]. - The net profit after deducting non-recurring gains and losses decreased by 8.84% to CNY 258,415,283.83 compared to the same period last year[7]. - The company reported a net profit of CNY 222,679,009.27 for the first nine months of 2016, compared to CNY 342,810,000.00 for the same period in 2015[29]. - The net profit for the third quarter was CNY 167,117,168.28, compared to CNY 53,023,138.53 in the previous year, representing a significant increase[31]. Cash Flow - The net cash flow from operating activities improved by 35.58%, reaching CNY -228,996,852.48[7]. - The cash inflow from operating activities for the first nine months reached ¥1,478,147,368.28, a significant increase from ¥938,725,527.36 in the same period last year, representing a growth of approximately 57.5%[36]. - The net cash flow from operating activities was negative at -¥228,996,852.48, an improvement compared to -¥355,474,709.74 in the previous year, indicating a reduction in cash outflow by about 35.5%[36]. - The net cash flow from investing activities showed a significant improvement of 65.02%, from -63,922,311.56 to -22,361,672.99, primarily due to the maturity of financial products[15]. - The cash inflow from investment activities totaled ¥742,823,807.37, compared to only ¥294,078.00 in the previous year, marking a substantial increase[36]. Assets and Liabilities - Total assets increased by 5.68% to CNY 6,287,903,081.62 compared to the end of the previous year[7]. - Current assets totaled CNY 4,614,192,454.47, compared to CNY 4,238,941,383.40 at the start of the year, reflecting a growth of approximately 8.85%[22]. - Total liabilities increased to CNY 3,614,192,454.47, compared to CNY 3,238,941,383.40 at the beginning of the year[22]. - Short-term borrowings increased by 48.21% to CNY 1,530,000,000.00, reflecting additional bank loans taken during the period[13]. - The company reported a significant increase in other receivables, rising to CNY 377,183,370.26 from CNY 74,936,707.98, which is an increase of approximately 403.5%[20]. Shareholder Information - The total number of shareholders reached 33,881 by the end of the reporting period[10]. - The largest shareholder, Hulin Chuangda Investment Co., Ltd., holds 67.83% of the shares, with 576,000,000 shares pledged[10]. Operating Costs and Income - Operating costs increased by 69.74% to CNY 519,754,270.51, attributed to higher sales revenue[14]. - Non-operating income surged by 439.99% to CNY 75,198,827.16, mainly due to increased government subsidies related to revenue[14]. - Tax expenses rose by 105.17% to CNY 110,743,422.07, driven by increased profits during the reporting period[14]. - The company recorded an investment income of CNY 28,596,101.45 during the period[33]. Legal and Compliance Issues - The company reported a significant increase in litigation costs, with a total of 12,316,527.49 yuan in liabilities and interest payments related to ongoing lawsuits[15]. - The company is currently involved in multiple legal disputes, including a case where it is required to pay 1,413,425.18 yuan in interest[16]. - The company has faced jurisdictional challenges in its legal proceedings, with recent rulings upholding the original court's jurisdiction[16]. - The company is actively managing its legal risks and financial liabilities associated with ongoing litigation[15]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development[29]. - The company is focused on improving its financial health through better cash management and resolution of legal disputes[15].

Financial Performance - The company's operating revenue for the first half of 2016 was ¥926,539,181.14, representing a 24.69% increase compared to ¥743,065,644.40 in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 13.01% to ¥208,204,644.94 from ¥239,354,197.80 year-on-year[19]. - The net profit after deducting non-recurring gains and losses was ¥175,702,651.40, down 25.53% from ¥235,940,222.19 in the previous year[19]. - The basic earnings per share decreased by 60.92% to ¥0.2452 from ¥0.6274 in the previous year[20]. - The diluted earnings per share also fell by 60.92% to ¥0.2452 compared to ¥0.6274 in the same period last year[20]. - The weighted average return on net assets decreased by 3.53 percentage points to 5.07% from 8.60% year-on-year[20]. - The total revenue for the first half of 2016 was CNY 924,412,710.93, representing a year-on-year increase of 24.41%[37]. - The company's net profit for the first half of 2016 is not explicitly stated, but the increase in revenue and costs indicates a potential impact on profitability[109]. Cash Flow and Investments - The net cash flow from operating activities was negative at -¥315,774,581.17, a decline of 93.09% compared to -¥163,538,395.32 in the same period last year[19]. - The company reported a net cash flow from investment activities of CNY 148,598,635.09, a substantial increase of 808.18% from CNY -20,983,119.44 in the previous year[32]. - The cash inflow from investment activities was CNY 595,785,171.60, compared to CNY 199,600.00 in the previous year[115]. - The cash outflow from investment activities was CNY 447,186,536.51, leading to a net cash flow from investment activities of CNY 148,598,635.09, an improvement from -CNY 20,983,119.44 in the previous year[115]. - The total cash inflow from financing activities was 1,230,000,000.00 RMB, compared to 2,361,066,800.00 RMB in the previous period[116]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,939,043,419.62, a slight decrease of 0.18% from ¥5,949,674,930.57 at the end of the previous year[19]. - The total current assets as of June 30, 2016, amounted to RMB 4,189,038,852.58, a slight decrease from RMB 4,238,941,383.40 at the beginning of the period[101]. - Total liabilities as of June 30, 2016, were RMB 3,619,274,497.08, compared to RMB 3,658,481,529.70 at the beginning of the period, showing a decrease of about 1.07%[102]. - The company's total assets were reported at RMB 5,939,043,419.62, slightly down from RMB 5,949,674,930.57[102]. - The cash and cash equivalents decreased from RMB 1,701,404,562.78 to RMB 1,383,805,343.20, reflecting a decline of approximately 18.68%[101]. Revenue Segmentation - Operating costs increased significantly by 101.32%, reaching CNY 365,258,203.83, up from CNY 181,429,577.99 in the previous year[31]. - The gross profit margin for the pharmaceutical industry segment was 74.01%, a decrease of 1.62 percentage points compared to the previous year[36]. - The pharmaceutical commercial segment's revenue increased by 29.72% to CNY 188,381,043.97, while its gross profit margin was 9.27%, down by 7.43 percentage points[36]. - Revenue from the Southwest region increased by 71.00%, and from the Northwest region by 162.01%, attributed to direct market promotion efforts and price adjustments[40]. - The revenue from biological preparations significantly decreased due to a drop in sales volume, primarily because of delayed bidding processes in some provinces[38]. Research and Development - Research and development expenses rose by 11.09% to CNY 20,453,902.89, compared to CNY 18,411,632.82 in the same period last year[32]. - The company has established partnerships with several prestigious research institutions to enhance its R&D capabilities, ensuring product technology remains advanced and complete[43]. Corporate Governance and Shareholder Relations - The company maintains a strict governance structure, ensuring independence from its controlling shareholders in various aspects[78]. - The company has established four specialized committees within the board to enhance governance and oversight[78]. - The company actively manages investor relations, ensuring timely communication and transparency with shareholders[79]. - The company has committed to not engaging in any business that competes with Zhenbao Island Pharmaceutical, ensuring no direct or indirect competition exists[70]. Future Plans and Commitments - The financing project for non-public issuance of A-shares is still in the preparatory stage following board and shareholder approvals[34]. - The company plans to terminate the "Compound Qilan Oral Liquid Industrialization Project" due to intense competition in the OTC drug market, which has affected expected sales growth[56]. - The company plans to initiate a share repurchase if the stock price remains below the net asset value for 20 consecutive trading days, with the repurchase amount capped at 20% of the previous year's net profit attributable to shareholders[73]. Legal and Compliance - There are no significant legal disputes or major contracts reported during the period[67]. - The company has fulfilled all commitments made by major shareholders regarding share transfer restrictions[68].